Raising $2.9M, Belgium's Cartagenia Opens US Office, Plans New Products for Clinical NGS Analysis | GenomeWeb

By Uduak Grace Thomas

Belgian clinical bioinformatics firm Cartagenia said this week that it has closed a €2.2 million ($2.9 million) round of financing that it will use to "strengthen" its market presence and advance its product development plans.

Half of the funds come from Cartagenia's existing shareholders — investment company PMV-VINNOF and seed capital group Gemma Frisius Fund — and its founders, while the rest came from a new addition to the roster, Quest for Growth, a private equity fund.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.